Trial Profile

A Multi-centre Prospective Non-interventional Study Investigating the Clinical Effectiveness of Ryzodeg (Insulin Degludec/Insulin Aspart) in Patients With Type 2 Diabetes Mellitus in a Real-world Setting

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2022 Results published in the Advances in Therapy
18 May 2022 Primary endpoint (Change in local laboratory measured glycosylated haemoglobin (HbA1c)) has been met as per results presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
18 May 2022 Results of an analysis assessed the impact of insulin degludec/insulin aspart (IDegAsp) treatment on healthcare resource utilization presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com